JP2016516722A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516722A5 JP2016516722A5 JP2016503069A JP2016503069A JP2016516722A5 JP 2016516722 A5 JP2016516722 A5 JP 2016516722A5 JP 2016503069 A JP2016503069 A JP 2016503069A JP 2016503069 A JP2016503069 A JP 2016503069A JP 2016516722 A5 JP2016516722 A5 JP 2016516722A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- item
- composition according
- pharmaceutical
- polysorbate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 115
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 86
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 63
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 61
- 229920001184 polypeptide Polymers 0.000 claims description 61
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 61
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 60
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 50
- 239000011780 sodium chloride Substances 0.000 claims description 43
- 208000032843 Hemorrhage Diseases 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 31
- 208000034158 bleeding Diseases 0.000 claims description 31
- 230000000740 bleeding effect Effects 0.000 claims description 31
- 229930006000 Sucrose Natural products 0.000 claims description 30
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 30
- 239000005720 sucrose Substances 0.000 claims description 30
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 26
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 26
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 26
- 229940068977 polysorbate 20 Drugs 0.000 claims description 26
- 229960002885 histidine Drugs 0.000 claims description 25
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 25
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 25
- 229920000053 polysorbate 80 Polymers 0.000 claims description 25
- 229940068968 polysorbate 80 Drugs 0.000 claims description 25
- 229940024606 amino acid Drugs 0.000 claims description 21
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 17
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 17
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 15
- 229960002713 calcium chloride Drugs 0.000 claims description 15
- 239000001110 calcium chloride Substances 0.000 claims description 15
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 15
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 claims description 11
- 229940052299 calcium chloride dihydrate Drugs 0.000 claims description 11
- 239000008176 lyophilized powder Substances 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 239000008227 sterile water for injection Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 208000031220 Hemophilia Diseases 0.000 claims description 2
- 208000009292 Hemophilia A Diseases 0.000 claims description 2
- 208000015294 blood coagulation disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 description 59
- 235000001014 amino acid Nutrition 0.000 description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010034827 Pharyngeal haemorrhage Diseases 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- 206010051297 Soft tissue haemorrhage Diseases 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 206010072043 Central nervous system haemorrhage Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010028024 Mouth haemorrhage Diseases 0.000 description 1
- 206010061298 Mucosal haemorrhage Diseases 0.000 description 1
- 206010028309 Muscle haemorrhage Diseases 0.000 description 1
- 229940031675 advate Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 208000002085 hemarthrosis Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 208000012310 mouth bleeding Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 210000000574 retroperitoneal space Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361800293P | 2013-03-15 | 2013-03-15 | |
| US61/800,293 | 2013-03-15 | ||
| US201361817085P | 2013-04-29 | 2013-04-29 | |
| US61/817,085 | 2013-04-29 | ||
| US201361829884P | 2013-05-31 | 2013-05-31 | |
| US61/829,884 | 2013-05-31 | ||
| US201361839477P | 2013-06-26 | 2013-06-26 | |
| US61/839,477 | 2013-06-26 | ||
| US201361863860P | 2013-08-08 | 2013-08-08 | |
| US61/863,860 | 2013-08-08 | ||
| US201361876927P | 2013-09-12 | 2013-09-12 | |
| US61/876,927 | 2013-09-12 | ||
| US201361879955P | 2013-09-19 | 2013-09-19 | |
| US61/879,955 | 2013-09-19 | ||
| US201361897742P | 2013-10-30 | 2013-10-30 | |
| US61/897,742 | 2013-10-30 | ||
| PCT/US2014/029354 WO2014144795A1 (en) | 2013-03-15 | 2014-03-14 | Factor viii polypeptide formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018082321A Division JP2018123161A (ja) | 2013-03-15 | 2018-04-23 | 第ｖｉｉｉ因子ポリペプチド製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516722A JP2016516722A (ja) | 2016-06-09 |
| JP2016516722A5 true JP2016516722A5 (OSRAM) | 2017-04-20 |
| JP6330026B2 JP6330026B2 (ja) | 2018-05-23 |
Family
ID=50771579
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503069A Active JP6330026B2 (ja) | 2013-03-15 | 2014-03-14 | 第ｖｉｉｉ因子ポリペプチド製剤 |
| JP2018082321A Ceased JP2018123161A (ja) | 2013-03-15 | 2018-04-23 | 第ｖｉｉｉ因子ポリペプチド製剤 |
| JP2020138637A Active JP6934994B2 (ja) | 2013-03-15 | 2020-08-19 | 第ｖｉｉｉ因子ポリペプチド製剤 |
| JP2021136162A Active JP7240457B2 (ja) | 2013-03-15 | 2021-08-24 | 第ｖｉｉｉ因子ポリペプチド製剤 |
| JP2023032892A Active JP7700164B2 (ja) | 2013-03-15 | 2023-03-03 | 第ｖｉｉｉ因子ポリペプチド製剤 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018082321A Ceased JP2018123161A (ja) | 2013-03-15 | 2018-04-23 | 第ｖｉｉｉ因子ポリペプチド製剤 |
| JP2020138637A Active JP6934994B2 (ja) | 2013-03-15 | 2020-08-19 | 第ｖｉｉｉ因子ポリペプチド製剤 |
| JP2021136162A Active JP7240457B2 (ja) | 2013-03-15 | 2021-08-24 | 第ｖｉｉｉ因子ポリペプチド製剤 |
| JP2023032892A Active JP7700164B2 (ja) | 2013-03-15 | 2023-03-03 | 第ｖｉｉｉ因子ポリペプチド製剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9623088B2 (OSRAM) |
| EP (3) | EP4122487A1 (OSRAM) |
| JP (5) | JP6330026B2 (OSRAM) |
| AU (4) | AU2014228506A1 (OSRAM) |
| CA (1) | CA2899737A1 (OSRAM) |
| CL (1) | CL2015002720A1 (OSRAM) |
| DK (1) | DK2968477T3 (OSRAM) |
| EA (2) | EA030357B1 (OSRAM) |
| ES (2) | ES2776195T3 (OSRAM) |
| HU (1) | HUE047933T2 (OSRAM) |
| LT (1) | LT2968477T (OSRAM) |
| PH (2) | PH12015501801B1 (OSRAM) |
| PL (2) | PL3666283T3 (OSRAM) |
| PT (2) | PT3666283T (OSRAM) |
| RS (1) | RS60003B1 (OSRAM) |
| SG (2) | SG11201505924TA (OSRAM) |
| SI (1) | SI2968477T1 (OSRAM) |
| TW (2) | TWI629993B (OSRAM) |
| UY (1) | UY35462A (OSRAM) |
| WO (1) | WO2014144795A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2506868T3 (da) * | 2009-12-06 | 2018-01-29 | Bioverativ Therapeutics Inc | Kimæriske og hybride faktor viii-fc-polypeptider og fremgangsmåder til anvendelse deraf |
| UY35463A (es) | 2013-03-15 | 2014-10-31 | Biogen Idec Inc | Formulaciones de polipéptido fc-factor ix. |
| PL3666283T3 (pl) | 2013-03-15 | 2022-10-03 | Bioverativ Therapeutics Inc. | Formulacje polipeptydu czynnika viii |
| CN106317226B (zh) | 2016-08-19 | 2017-09-05 | 安源医药科技（上海）有限公司 | 用于构建融合蛋白的连接肽 |
| CN106279437B (zh) * | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| WO2018102743A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| US12257288B2 (en) | 2016-12-02 | 2025-03-25 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
| JP7039308B2 (ja) * | 2017-02-08 | 2022-03-22 | 三洋化成工業株式会社 | 細胞培養用担体 |
| MY203184A (en) | 2017-08-09 | 2024-06-13 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
| US10603275B2 (en) * | 2017-11-07 | 2020-03-31 | Rani Therapeutics, Llc | Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device |
| SG11202010767SA (en) | 2018-05-18 | 2020-11-27 | Bioverativ Therapeutics Inc | Methods of treating hemophilia a |
| MX2021001599A (es) | 2018-08-09 | 2021-07-02 | Bioverativ Therapeutics Inc | Moleculas de acido nucleico y sus usos para la terapia genica no viral. |
| CA3115535A1 (en) * | 2018-10-23 | 2020-04-30 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor viii function |
| US20220088085A1 (en) * | 2019-02-28 | 2022-03-24 | Public University Corporation Yokohama City University | Composition for treating blood coagulation and/or complement disorders |
| KR20220009389A (ko) | 2019-04-17 | 2022-01-24 | 코디악 바이오사이언시즈, 인크. | 엑소좀 및 aav 의 조성물 |
| WO2020257462A1 (en) | 2019-06-19 | 2020-12-24 | Bioverativ Therapeutics Inc. | Recombinant factor viii-fc for treating hemophilia and low bone mineral density |
| KR20230159285A (ko) * | 2022-05-10 | 2023-11-21 | 주식회사 녹십자 | 혈장 단백질의 동결 건조를 위한 신규한 액상 제형물 |
| WO2023219378A1 (ko) * | 2022-05-10 | 2023-11-16 | 주식회사 녹십자 | 혈장 단백질에 대한 신규한 액상 제형물 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| DE3683980D1 (de) | 1985-04-12 | 1992-04-02 | Genetics Inst | Neue prokoagulierungsproteine. |
| KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
| WO1987004187A1 (en) | 1986-01-03 | 1987-07-16 | Genetics Institute, Inc. | METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS |
| US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| US5610278A (en) | 1986-06-24 | 1997-03-11 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
| US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| IE69026B1 (en) | 1987-06-12 | 1996-08-07 | Immuno Ag | Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
| FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
| US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
| US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
| CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
| DK0461200T3 (da) | 1989-02-21 | 1997-03-10 | Univ Washington | Modificerede former af reproduktionshormoner |
| SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| CA2106079C (en) | 1991-03-15 | 2000-04-25 | Robert C. Thompson | Pegylation of polypeptides |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
| US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
| US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| SK282483B6 (sk) * | 1992-10-02 | 2002-02-05 | Genetics Institute, Inc. | Stabilná kompozícia koagulačného faktora VIII, spôsob jej prípravy a stabilizácie |
| US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| IL113010A0 (en) * | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
| US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
| DK1820516T3 (da) | 1999-02-22 | 2013-10-28 | Univ Connecticut | Nye albuminfrie faktor VIII-præparater |
| CN1406249B (zh) | 2000-02-11 | 2010-06-16 | 默克专利股份有限公司 | 增加基于抗体的融合蛋白的循环半衰期 |
| EP2277910A1 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| GB0207092D0 (en) | 2002-03-26 | 2002-05-08 | Sod Conseils Rech Applic | Stable pharmaceutical composition containing factor VIII |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| HUE026384T2 (en) | 2003-05-06 | 2016-06-28 | Biogen Hemophilia Inc | VII coagulation factor-FC chimeric proteins for the treatment of hemostasis disorder |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| KR20130026498A (ko) * | 2003-12-19 | 2013-03-13 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물 |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| ES2633916T3 (es) | 2004-11-12 | 2017-09-26 | Bayer Healthcare Llc | Modificación de FVIII dirigida al sitio |
| WO2007092772A2 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Inc. | Protein formulations |
| US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
| JP5448839B2 (ja) * | 2006-12-22 | 2014-03-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | インビボで長い半減期を有する修飾された凝固因子 |
| ES2362386T3 (es) | 2007-06-21 | 2011-07-04 | Technische Universität München | Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro. |
| US8239182B2 (en) | 2007-12-04 | 2012-08-07 | Spansion Llc | Data transmission system-on-chip memory model based validation |
| EP2242505A4 (en) | 2008-01-08 | 2012-03-07 | Biogenerix Ag | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES |
| CN102482340B (zh) | 2009-04-06 | 2015-05-13 | 诺沃—诺迪斯克有限公司 | 因子viii蛋白向血小板的靶向递送 |
| DK2506868T3 (da) * | 2009-12-06 | 2018-01-29 | Bioverativ Therapeutics Inc | Kimæriske og hybride faktor viii-fc-polypeptider og fremgangsmåder til anvendelse deraf |
| PL3513804T3 (pl) * | 2011-07-08 | 2022-07-11 | Bioverativ Therapeutics Inc. | Chimeryczne i hybrydowe polipeptydy czynnika VIII i sposoby ich stosowania |
| EP2768853A1 (en) | 2011-10-18 | 2014-08-27 | CSL Limited | Method for improving the stability of purified factor viii after reconstitution |
| WO2014026954A1 (en) * | 2012-08-13 | 2014-02-20 | Novo Nordisk A/S | Liquid factor viii formulations |
| EP2914293A4 (en) * | 2012-10-30 | 2016-04-20 | Biogen Ma Inc | METHOD OF USE OF FVIII POLYPEPTIDE |
| PL3666283T3 (pl) | 2013-03-15 | 2022-10-03 | Bioverativ Therapeutics Inc. | Formulacje polipeptydu czynnika viii |
-
2014
- 2014-03-14 PL PL19212900.5T patent/PL3666283T3/pl unknown
- 2014-03-14 UY UY0001035462A patent/UY35462A/es not_active Application Discontinuation
- 2014-03-14 RS RS20200243A patent/RS60003B1/sr unknown
- 2014-03-14 SG SG11201505924TA patent/SG11201505924TA/en unknown
- 2014-03-14 WO PCT/US2014/029354 patent/WO2014144795A1/en not_active Ceased
- 2014-03-14 DK DK14725816.4T patent/DK2968477T3/da active
- 2014-03-14 SG SG10201805207QA patent/SG10201805207QA/en unknown
- 2014-03-14 EP EP22176875.7A patent/EP4122487A1/en active Pending
- 2014-03-14 EA EA201591439A patent/EA030357B1/ru unknown
- 2014-03-14 ES ES14725816T patent/ES2776195T3/es active Active
- 2014-03-14 EP EP19212900.5A patent/EP3666283B1/en active Active
- 2014-03-14 EA EA201890671A patent/EA201890671A1/ru unknown
- 2014-03-14 US US14/213,180 patent/US9623088B2/en active Active
- 2014-03-14 PL PL14725816T patent/PL2968477T3/pl unknown
- 2014-03-14 LT LTEP14725816.4T patent/LT2968477T/lt unknown
- 2014-03-14 TW TW103109616A patent/TWI629993B/zh active
- 2014-03-14 AU AU2014228506A patent/AU2014228506A1/en not_active Abandoned
- 2014-03-14 ES ES19212900T patent/ES2926798T3/es active Active
- 2014-03-14 CA CA2899737A patent/CA2899737A1/en active Pending
- 2014-03-14 PT PT192129005T patent/PT3666283T/pt unknown
- 2014-03-14 EP EP14725816.4A patent/EP2968477B1/en active Active
- 2014-03-14 HU HUE14725816A patent/HUE047933T2/hu unknown
- 2014-03-14 PT PT147258164T patent/PT2968477T/pt unknown
- 2014-03-14 SI SI201431514T patent/SI2968477T1/sl unknown
- 2014-03-14 JP JP2016503069A patent/JP6330026B2/ja active Active
- 2014-03-14 TW TW107113370A patent/TWI690325B/zh active
-
2015
- 2015-08-14 PH PH12015501801A patent/PH12015501801B1/en unknown
- 2015-09-15 CL CL2015002720A patent/CL2015002720A1/es unknown
-
2017
- 2017-03-09 US US15/455,043 patent/US10786554B2/en active Active
-
2018
- 2018-04-23 JP JP2018082321A patent/JP2018123161A/ja not_active Ceased
-
2019
- 2019-04-16 AU AU2019202656A patent/AU2019202656B2/en active Active
- 2019-10-30 PH PH12019502452A patent/PH12019502452A1/en unknown
-
2020
- 2020-08-14 US US16/993,979 patent/US12403183B2/en active Active
- 2020-08-19 JP JP2020138637A patent/JP6934994B2/ja active Active
-
2021
- 2021-08-24 JP JP2021136162A patent/JP7240457B2/ja active Active
- 2021-11-29 AU AU2021277601A patent/AU2021277601B2/en active Active
-
2023
- 2023-03-03 JP JP2023032892A patent/JP7700164B2/ja active Active
-
2025
- 2025-05-30 AU AU2025204069A patent/AU2025204069A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516722A5 (OSRAM) | ||
| JP7240457B2 (ja) | 第ｖｉｉｉ因子ポリペプチド製剤 | |
| JP7741145B2 (ja) | 第ｉｘ因子ポリペプチド製剤 | |
| JP7715635B2 (ja) | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 | |
| JP2019214592A (ja) | ベンダムスチンの製剤 | |
| US11993640B2 (en) | Treating inflammatory lung disease | |
| BR112020003670A2 (pt) | receptores de interferon solúveis e usos dos mesmos | |
| CA3128113A1 (en) | Pharmaceutical taci-fc fusion protein formulation | |
| JP2024123116A (ja) | 再生不良性貧血を治療するための医薬組成物 | |
| EP2240195A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) | |
| CN102552883A (zh) | 一种多肽复合物、药物组合物、其制备方法和应用 | |
| US11554156B2 (en) | Pharmaceutical formulations of C1 esterase inhibitor | |
| AU2016221627A1 (en) | Pharmaceutical formulations of C1 esterase inhibitor | |
| ES3041501T3 (en) | Hmgb1 derived peptide for treating or preventing a cartilage disorder | |
| Soori et al. | Continuous-infusion floxuridine and alpha interferon in metastatic renal cancer: a national biotherapy study group phase II study | |
| KR20250086669A (ko) | 혈관절증의 예방 또는 치료용 약학 조성물 | |
| HK40059370A (en) | Pharmaceutical composition for treating aplastic anemia | |
| EA046878B1 (ru) | Фармацевтическая композиция для лечения апластической анемии | |
| CN118973600A (zh) | 用于脐带血移植后的血细胞恢复的药物组合物 |